ROS1+ NSCLC were mutually exclusive with known actionable oncogenic alterations in EGFR, KRAS, ALK, RET, NTRK or NRG. TP53 mutations (29.1%) were the most common co-mutations followed by SETD2 mutations (7.3%), ARIAD1A mutations (6.3%) and U2AF1 (5.6%). This evidence concerns the gene KRAS and non-small cell lung carcinoma.